This finding introduces a new perspective into the investigation of drug resistance in CRC and lays a theoretical foundation for exploring innovative therapeutic approaches that leverage miR-1247-3p and CCND1 as potential targets. This evidence concerns the gene CCND1 and colorectal carcinoma.